Subtopic Deep Dive

Anti-Angiogenic Therapy Resistance
Research Guide

What is Anti-Angiogenic Therapy Resistance?

Anti-angiogenic therapy resistance refers to tumor adaptive mechanisms that evade VEGF pathway inhibition, including upregulation of alternative angiogenic factors, vessel co-option, and enhanced metastasis.

Tumors develop resistance to drugs like bevacizumab through hypoxia-induced pathways and PI3K/AKT/mTOR activation (Bergers and Hanahan, 2008; 2886 citations). Clinical trials show prolonged progression-free survival but limited overall survival gains (Miller et al., 2007; 3031 citations). Over 10 key papers document these modes since 2000.

Curated Papers

Key Challenges

Why It Matters

Resistance limits bevacizumab efficacy in breast and cervical cancers, extending median survival by only 3.7 months in cervical cases (Tewari et al., 2014; 1457 citations). Understanding mechanisms like hypoxia-driven angiogenesis enables combination therapies targeting PI3K/AKT/mTOR (Karar and Maity, 2011; 1386 citations). Biomarker identification from trial data improves patient selection for anti-VEGF drugs (Miller et al., 2007).

Key Research Challenges

Alternative Angiogenic Pathways

Tumors upregulate non-VEGF factors post-bevacizumab treatment. Bergers and Hanahan (2008) identify multiple compensatory pathways. This reduces single-agent efficacy in clinical settings.

Vessel Co-option Mechanisms

Cancers bypass sprouting angiogenesis by co-opting existing vessels. Muz et al. (2015; 2003 citations) link hypoxia to this shift. It promotes metastasis and therapy evasion.

Hypoxia-Induced Resistance

Low oxygen triggers epithelial-to-mesenchymal transition and dysfunctional vascularization. Muz et al. (2015) detail hypoxia's role in progression. Ferrara (2004; 3650 citations) shows VEGF transcription under hypoxia.

Essential Papers

Vascular Endothelial Growth Factor: Basic Science and Clinical Progress

Napoleone Ferrara · 2004 · Endocrine Reviews · 3.6K citations

Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an angiogenic inducer in a variety of in vivo models. Hypoxia has been shown to be a major inducer of ...

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · 2007 · New England Journal of Medicine · 3.0K citations

Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone. (ClinicalTrials.gov num...

Modes of resistance to anti-angiogenic therapy

Gabriele Bergers, Douglas Hanahan · 2008 · Nature reviews. Cancer · 2.9K citations

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy

Barbara Muz, Pilar de la Puente, Feda Azab et al. · 2015 · Hypoxia · 2.0K citations

Hypoxia is a non-physiological level of oxygen tension, a phenomenon common in a majority of malignant tumors. Tumor-hypoxia leads to advanced but dysfunctional vascularization and acquisition of e...

Tumor angiogenesis: causes, consequences, challenges and opportunities

Roberta Lugano, Mohanraj Ramachandran, Anna Dimberg · 2019 · Cellular and Molecular Life Sciences · 1.8K citations

Abstract Tumor vascularization occurs through several distinct biological processes, which not only vary between tumor type and anatomic location, but also occur simultaneously within the same canc...

Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness

Hiroya Hashizume, Peter Bałuk, Shunichi Morikawa et al. · 2000 · American Journal Of Pathology · 1.7K citations

Improved Survival with Bevacizumab in Advanced Cervical Cancer

Krishnansu S. Tewari, Michael W. Sill, Harry J. Long et al. · 2014 · New England Journal of Medicine · 1.5K citations

The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall surv...

Reading Guide

Foundational Papers

Start with Ferrara (2004; 3650 citations) for VEGF basics, Bergers and Hanahan (2008; 2886 citations) for resistance modes, and Miller et al. (2007; 3031 citations) for clinical evidence.

Recent Advances

Study Lugano et al. (2019; 1813 citations) on tumor vascularization processes and Muz et al. (2015; 2003 citations) on hypoxia's role in resistance.

Core Methods

Key techniques include clinical trial PFS/OS analysis (Tewari et al., 2014), pathway inhibition models (Karar and Maity, 2011), and vessel imaging (Hashizume et al., 2000).

How PapersFlow Helps You Research Anti-Angiogenic Therapy Resistance

Discover & Search

Research Agent uses searchPapers for 'anti-angiogenic resistance Bergers Hanahan' to retrieve the 2886-citation paper, then citationGraph reveals 200+ downstream works on vessel co-option, and findSimilarPapers surfaces Muz et al. (2015) on hypoxia mechanisms.

Analyze & Verify

Analysis Agent applies readPaperContent to Bergers and Hanahan (2008) for resistance modes extraction, verifyResponse with CoVe cross-checks claims against Miller et al. (2007) trial data, and runPythonAnalysis plots survival curves from Tewari et al. (2014) with GRADE scoring for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in PI3K/AKT targeting post-VEGF inhibition, flags contradictions between preclinical models and trials, while Writing Agent uses latexEditText for manuscript revisions, latexSyncCitations for 10+ references, and latexCompile for figure-inclusive PDFs; exportMermaid diagrams resistance pathways.

Use Cases

"Analyze survival data from bevacizumab breast cancer trials for resistance patterns"

Research Agent → searchPapers 'Miller 2007 bevacizumab' → Analysis Agent → readPaperContent + runPythonAnalysis (pandas on PFS/OS curves) → statistical output with p-values and GRADE B evidence.

"Draft review section on hypoxia in anti-angiogenic resistance with citations"

Synthesis Agent → gap detection on Muz 2015 + Ferrara 2004 → Writing Agent → latexEditText 'hypoxia VEGF resistance' → latexSyncCitations (10 papers) → latexCompile → camera-ready LaTeX section.

"Find code for modeling vessel co-option in tumors"

Research Agent → searchPapers 'vessel co-option angiogenesis code' → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for simulation models.

Automated Workflows

Deep Research workflow scans 50+ papers on VEGF resistance via searchPapers → citationGraph → structured report with GRADE tables on Bergers (2008) citations. DeepScan applies 7-step CoVe to verify hypoxia claims in Muz et al. (2015) against trial data. Theorizer generates hypotheses on PI3K/AKT combo therapies from Karar and Maity (2011).

Try Doxa for Anti-Angiogenic Therapy Resistance Research

Frequently Asked Questions

What defines anti-angiogenic therapy resistance?

Tumors evade VEGF inhibitors via alternative factors, vessel co-option, and metastasis, as defined by Bergers and Hanahan (2008).

What methods study this resistance?

Clinical trials like Miller et al. (2007) measure PFS/OS; preclinical models assess hypoxia (Muz et al., 2015) and pathway activation (Karar and Maity, 2011).

What are key papers?

Bergers and Hanahan (2008; 2886 citations) on resistance modes; Miller et al. (2007; 3031 citations) on bevacizumab trials; Ferrara (2004; 3650 citations) on VEGF basics.